January 7, 2020
Urovant Sciences, now a consolidated subsidiary of Sumitomo Dainippon Pharma, has filed a new drug application in the US for its overactive bladder (OAB) treatment vibegron. The submission on December 30 seeks approval for once-daily vibegron to treat patients with...read more